Man­u­fac­tur­ers, in­dus­try groups com­ment on FDA’s con­trol over ni­trosamines in drug prod­ucts

The FDA has re­ceived com­ments from man­u­fac­tur­ers and oth­er in­dus­try play­ers on how best to tack­le im­pu­ri­ties known as ni­trosamines in drugs.

In May, the FDA sought out com­ments from man­u­fac­tur­ers and oth­er stake­hold­ers on how best to deal with the po­ten­tial­ly can­cer-caus­ing sub­stances af­ter it pre­vi­ous­ly is­sued guid­ance. The reg­u­la­tor pub­lished the com­ments ear­li­er this month.

The FDA first be­gan in­ves­ti­gat­ing ni­trosamines in 2018 over con­cerns about im­pu­ri­ties in the blood-pres­sure drug val­sar­tan. It then put out guid­ance for man­u­fac­tur­ers in 2020 that re­quired them to con­duct risk as­sess­ments of all ap­proved or mar­ket­ed prod­ucts to de­tect po­ten­tial­ly can­cer-caus­ing ni­trosamine im­pu­ri­ties and en­sure that their prod­ucts have ac­cept­able lev­els of the im­pu­ri­ties.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER